Response to first-line pembrolizumab in metastatic KRAS-mutated non-small-cell lung cancer.
Future Oncol
; 20(7): 373-380, 2024 Mar.
Article
in En
| MEDLINE
| ID: mdl-38445372
ABSTRACT
Aims:
This retrospective study aims to identify a possible predictive role of KRAS mutations in non-small-cell lung cancer in response to first-line pembrolizumab, either as monotherapy or combined with chemotherapy.Methods:
Patients received pembrolizumab alone (n = 213) or associated with chemotherapy (n = 81).Results:
A mutation in the KRAS gene was detected in 27% of patients. In patients on pembrolizumab alone, median progression-free survival in KRAS-mutated cases was longer than in wild-type cases (11.3 vs 4.4 months; p = 0.019), whereas median overall survival did not reach statistical significance (22.1 vs 12.5 months; p = 0.119). Patients receiving chemo-immunotherapy with KRAS-positive tumors had a similar progression-free survival (9.7 vs 7.3 months; p = 0.435); overall survival data were immature.Conclusion:
This study suggests a correlation between KRAS status and response to pembrolizumab.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Antibodies, Monoclonal, Humanized
/
Lung Neoplasms
Limits:
Humans
Language:
En
Journal:
Future Oncol
Year:
2024
Document type:
Article
Affiliation country:
Italy
Country of publication:
United kingdom